AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat ...

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug ...

AstraZeneca has returned to recent collaborator CSPC with $110 million in upfront cash to find new oral drugs for a range of chronic diseases.

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's rules on approving new medicines as well as a row over drug prices.

AstraZeneca is paying China’s CSPC Pharmaceutical $110 million upfront to discover new oral drugs for chronic diseases, including one potential project for immunological diseases. The deal ...

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the discovery of novel oral therapies for chronic diseases. The partnership, ...

On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.